Heidelberg Pharma AG

Heidelberg Pharma maintains a strong liquidity position, with cash and equivalents amounting to €42.6 million, which is significantly higher than its total liabilities of €30.8 million, resulting in a current ratio of 6.13. The company's price-to-book ratio of 3.01 suggests that the market is valuing the company at a premium to its book value, which may reflect expectations of future growth or intangible assets. However, the company's negative operating income of €4.56 million and net loss of €4.17 million indicate that it is not currently generating positive earnings.

The company's return on equity (ROE) of -10.13% and return on assets (ROA) of -5.8% are significantly below the industry median for biotechnology firms, which typically report positive ROE and ROA figures. This suggests that Heidelberg Pharma is underperforming in terms of profitability and asset utilization. The company's gross profit of €1.46 million on revenue of €2.79 million indicates a gross margin of approximately 52.4%, which is in line with industry norms for early-stage biotechnology firms.

Heidelberg Pharma's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the provided data. This lack of diversification may expose the company to higher risk if its primary therapeutic area or market experiences a downturn. The company's operating cash flow of -€16.92 million and free cash flow of -€3.99 million indicate that it is currently not generating positive cash from operations, which is common for companies in the development stage.

Looking ahead, the company is expected to maintain a negative growth trajectory, with no positive revenue growth indicated in the provided data. The company's capital expenditures of -€85,080 suggest minimal investment in physical assets, which is consistent with its focus on research and development. The company's debt-to-equity ratio of 0.52 indicates a relatively conservative capital structure, with equity financing playing a larger role in its capital base.

The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative operating income and net loss suggest that it may need to raise additional capital in the future, which could lead to dilution for existing shareholders. The company's recent financial performance and lack of profitability may also impact its ability to secure favorable financing terms.

Recent analyst estimates indicate a mean price target of €5.50, which is significantly higher than the current market price of €2.65. This suggests that analysts have a positive outlook on the company's future performance, despite its current financial challenges. The company has not issued any recent filings or transcripts that would indicate significant changes in its business strategy or financial position.

Analysts project 112.4% upside to a consensus target price of EUR 5.50, signaling strong market confidence in future recovery.

Operating and net margins exceed cohort medians, indicating relatively better profitability efficiency compared to 372 biotechnology peers.

Cash conversion metrics rank best-in-class within the cohort, highlighting efficient capital management despite ongoing operational losses.

Low dilution and liquidity risks provide a stable capital structure foundation, reducing immediate threats to shareholder equity value.

Long-term debt surged to EUR 36.9 million, creating a high credit risk profile and increasing financial leverage burdens.

Debt-to-equity ratio of 0.52 places the company in the bottom quartile of its cohort, signaling excessive leverage relative to peers.

Revenue €1.5M, −78,7% YoY; Operating income −103,7% YoY.

• ▍Revenue €1.5M, −78,7% YoY
• ▍Operating income −103,7% YoY
• ▍Net income −118,2% YoY
• ▍Free cash flow −120,0% YoY
• ▍Net margin -2901.2%

Revenue €6.8M, −30,5% YoY; Operating income +2,6% YoY.

• ▍Revenue €6.8M, −30,5% YoY
• ▍Operating income +2,6% YoY
• ▍Net income +4,7% YoY
• ▍Free cash flow +7,0% YoY
• ▍Net margin -283.0%

Revenue €9.9M, −46,8% YoY; Operating income −23,4% YoY.

• ▍Revenue €9.9M, −46,8% YoY
• ▍Operating income −23,4% YoY
• ▍Net income −3,3% YoY
• ▍Free cash flow −4,4% YoY
• ▍Net margin -206.4%

Revenue €18.5M, +958,0% YoY; Operating income +33,0% YoY.

• ▍Revenue €18.5M, +958,0% YoY
• ▍Operating income +33,0% YoY
• ▍Net income +24,6% YoY
• ▍Free cash flow +26,5% YoY
• ▍Net margin -106.4%

Revenue €1.7M; Operating income -€25.6M.

• ▍Revenue €1.7M
• ▍Operating income -€25.6M
• ▍Net margin -1493.8%